These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18752509)

  • 1. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
    Uusitalo H; Kaarniranta K; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.
    Kaarniranta K; Ikäheimo K; Mannermaa E; Ropo A
    Clin Pharmacokinet; 2016 Apr; 55(4):485-94. PubMed ID: 26391697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
    Pellinen P; Lokkila J
    Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
    Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
    Rolle T; Spinetta R; Nuzzi R
    BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery.
    Maca SM; Amon M; Findl O; Kahraman G; Barisani-Asenbauer T
    Am J Ophthalmol; 2010 May; 149(5):777-84. PubMed ID: 20152959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spanish multicenter tafluprost tolerability study.
    Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
    Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers.
    Kopczynski C; Novack GD; Swearingen D; van Haarlem T
    Br J Ophthalmol; 2013 May; 97(5):567-72. PubMed ID: 23435190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
    Swymer C; Neville MW
    Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.